Trade continues to be the least problematic aspect of the EU-China economic relationship. The BRI offers potential trade gains for Europe by improving physical connectivity with countries along the route to China, but it also poses challenges for the EU. While Chinese investment in Europe is growing and has focused strongly on technology, it raises the question of whether the EU should fear losing its technological edge, especially when Chinese state-owned companies might distort competition through foreign acquisitions.

The pharmaceutical industry is a key partner in Europe’s fight against disease, developing new treatments and cures for patients across Europe. It is imperative that Europe remains a competitive destination for medical research and development by maintaining, sustaining and developing a predictable, robust regulatory and innovation-supportive incentives environment.